Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2

Anne Vest Sørensen; Gregers G Hermann; Niels Jensen; Astrid Petersen; Niels Henrik Spliid; Rickard Sandin; Kirsten Fode; Poul F Geertsen

doi:10.1016/j.ejca.2013.10.010

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2

Anne Vest Sørensen, Gregers G Hermann, Niels Jensen, Astrid Petersen, Niels Henrik Spliid, Rickard Sandin, Kirsten Fode, Poul F Geertsen

Oncology

63 Citations (Scopus)

Abstract

To evaluate the implementation of targeted therapy on overall survival (OS) in a complete national cohort of patients with metastatic renal cell carcinoma (mRCC).

Original language	English
Journal	European journal of cancer (Oxford, England : 1990)
Volume	50
Issue number	3
Pages (from-to)	553-62
Number of pages	10
ISSN	0959-8049
DOIs	https://doi.org/10.1016/j.ejca.2013.10.010
Publication status	Published - Feb 2014

Access to Document

10.1016/j.ejca.2013.10.010

Cite this

Sørensen, A. V., Hermann, G. G., Jensen, N., Petersen, A., Spliid, N. H., Sandin, R., Fode, K., & Geertsen, P. F. (2014). Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2. European journal of cancer (Oxford, England : 1990), 50(3), 553-62. https://doi.org/10.1016/j.ejca.2013.10.010

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma : Results from the Danish Renal Cancer Group (DARENCA) study-2. / Sørensen, Anne Vest ; Hermann, Gregers G; Jensen, Niels et al.

In: European journal of cancer (Oxford, England : 1990), Vol. 50, No. 3, 02.2014, p. 553-62.

Research output: Contribution to journal › Journal article › Research › peer-review

Sørensen, AV , Hermann, GG, Jensen, N, Petersen, A, Spliid, NH, Sandin, R, Fode, K & Geertsen, PF 2014, 'Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2', European journal of cancer (Oxford, England : 1990), vol. 50, no. 3, pp. 553-62. https://doi.org/10.1016/j.ejca.2013.10.010

Sørensen AV , Hermann GG, Jensen N, Petersen A, Spliid NH, Sandin R et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2. European journal of cancer (Oxford, England : 1990). 2014 Feb;50(3):553-62. https://doi.org/10.1016/j.ejca.2013.10.010

@article{1c038adc1c8642f186385789c92e8397,

title = "Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2",

abstract = "To evaluate the implementation of targeted therapy on overall survival (OS) in a complete national cohort of patients with metastatic renal cell carcinoma (mRCC).",

author = "S{\o}rensen, {Anne Vest} and Hermann, {Gregers G} and Niels Jensen and Astrid Petersen and Spliid, {Niels Henrik} and Rickard Sandin and Kirsten Fode and Geertsen, {Poul F}",

year = "2014",

month = feb,

doi = "10.1016/j.ejca.2013.10.010",

language = "English",

volume = "50",

pages = "553--62",

journal = "European Journal of Cancer, Supplement",

issn = "0959-8049",

publisher = "Pergamon",

number = "3",

}

TY - JOUR

T1 - Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma

T2 - Results from the Danish Renal Cancer Group (DARENCA) study-2

AU - Sørensen, Anne Vest

AU - Hermann, Gregers G

AU - Jensen, Niels

AU - Petersen, Astrid

AU - Spliid, Niels Henrik

AU - Sandin, Rickard

AU - Fode, Kirsten

AU - Geertsen, Poul F

PY - 2014/2

Y1 - 2014/2

N2 - To evaluate the implementation of targeted therapy on overall survival (OS) in a complete national cohort of patients with metastatic renal cell carcinoma (mRCC).

AB - To evaluate the implementation of targeted therapy on overall survival (OS) in a complete national cohort of patients with metastatic renal cell carcinoma (mRCC).

U2 - 10.1016/j.ejca.2013.10.010

DO - 10.1016/j.ejca.2013.10.010

M3 - Journal article

C2 - 24215846

VL - 50

SP - 553

EP - 562

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

SN - 0959-8049

IS - 3

ER -

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: Results from the Danish Renal Cancer Group (DARENCA) study-2

Abstract

Access to Document

Fingerprint

Cite this